Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL6069108 | 0.97 | TTR (0.40) | TTRSMN1; SMN2POLBTSHR | |
| Oxirane SCHEMBL28302535 | 0.93 | TTR (0.33) | TTR | |
| Tetrahydrofuran SCHEMBL3369904 | 0.87 | ALDH1A1 (0.50) | — | |
| Tetrahydrofuran SCHEMBL15993933 | 0.87 | ALDH1A1 (0.50) | — | |
| SCHEMBL971171 | 0.86 | TSHR (0.43) | TSHR | |
| SCHEMBL8530499 | 0.84 | ALDH1A1 (0.47) | — | |
| Tetrahydrofuran SCHEMBL1896714 | 0.82 | ALDH1A1 (0.44) | POLB | |
| SCHEMBL971172 | 0.81 | TSHR (0.36) | POLBTSHRMEN1KMT2A | |
| SCHEMBL971173 | 0.81 | — | — | |
| Fluoride SCHEMBL22345959 | 0.80 | ALDH1A1 (0.36) | POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194626-A1 | METHOD FOR PRODUCING AMIDO-ZINC HALIDE/ALKALI- METAL HALIDE COMPOUNDS | Rockwood Lithium GmbH (DE) | 2014-07-10 | — | — | US | claimed |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2024-05-14 | — | — | US | disclosed |
| WO-2024038810-A1 | POSITIVE-TYPE PHOTOSENSITIVE COMPOSITION, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND COLORANT | 東レ株式会社 | 2024-02-22 | — | — | WO | disclosed |
| WO-2023210740-A1 | BENZOTHIOPHENE COMPOUND | 第一三共株式会社 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023195319-A1 | POSITIVE PHOTOSENSITIVE PIGMENT COMPOSITION, CURED FILM CONTAINING CURED PRODUCT THEREOF, AND ORGANIC EL DISPLAY DEVICE | 東レ株式会社 | 2023-10-12 | — | — | WO | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| EP-3735413-B1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021139795-A1 | METHOD FOR PREPARING PYRROLIDINYL UREA DERIVATIVE | 漳州片仔癀药业股份有限公司 | 2021-07-15 | — | — | WO | disclosed |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | disclosed |
| CN-107922396-A | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2018-04-17 | — | — | CN | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6034021-A | COORDINATION CATALYST | THE DOW CHEMICAL COMPANY (US) | 2000-03-07 | — | — | US | disclosed |
| WO-1999043356-A1 | ANTIBIOTIC-LIGAND CONJUGATES AND METHODS OF USE THEREOF | HSC RESEARCH DEVELOPMENT LIMITED PARTNERSHIP (CA) | 1999-09-02 | — | — | WO | disclosed |
| US-5760198-A | Process for preparation of 4\"-deoxyerythromycins A and B | ABBOTT LABORATORIES (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0232875-B1 | METHOD FOR REMOVING LIPOPROTEINS USING AN ADSORBENT | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-05-08 | — | — | EP | disclosed |
| US-4814077-A | CELLULOSE OR AGAROSE SURFACE TREATED WITH AROMATIC AMINE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-03-21 | — | — | US | disclosed |
| EP-0232875-A2 | Method for removing lipoproteins using an adsorbent | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-08-19 | — | — | EP | disclosed |
| EP-0196101-A2 | Purification of synthetic oligomers | CHIRON CORPORATION (US) | 1986-10-01 | — | — | EP | disclosed |
| US-4380629-A | Styryl-like compounds showing a color-developing and bleaching behavior with improved stability and prolonged lifetime | MATSUSHITA ELECTRIC INDUSTRIAL COMPANY, LIMITED (JP) | 1983-04-19 | — | — | US | disclosed |
| US-4115538-A | RADIOIMMUNOASSAY; ADENOSINE-3',5'-CYCLIC MONOPHOSPHATE, GUANOSINE-3',5'-CYCLIC MONOPHOSPHATE | YAMASU SHOYU KABUSHIKI KAISHA (JP) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194626-A1 | METHOD FOR PRODUCING AMIDO-ZINC HALIDE/ALKALI- METAL HALIDE COMPOUNDS | ZRANB2, ZKSCAN2, SLC39A11 | TTR 1109/4885SMN1; SMN2 2749/4885POLB 1265/4885 |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | TTR 1225/4885SMN1; SMN2 2893/4885POLB 1062/4885 |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA3, ADORA1 | TTR 1030/4885SMN1; SMN2 2901/4885POLB 1649/4885 |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA1, ADORA2B | TTR 1225/4885SMN1; SMN2 2893/4885POLB 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.